Artemisia Annua Flowering Top

Allergenic Testing (Diagnosis)

For diagnostic purposes, the Artemisia Annua Flowering Top extract is typically used at a concentration of 1:10 or 1:20 w/v for skin prick testing. A single drop is applied to the forearm or back, and the skin is pricked through the drop. A positive result is usually defined as a wheal 3mm larger than the negative control.

Allergen Immunotherapy (Treatment)

Dosing for immunotherapy follows a 'build-up' phase and a 'maintenance' phase.

• Build-up Phase: Starts with a very dilute solution (e.g., 1:100,000 w/v). Injections are given 1-2 times per week, with the dose increasing by 50-100% each time, provided no significant local reactions occur.
• Maintenance Phase: Once the target dose is reached (typically 0.5 mL of a 1:100 or 1:20 w/v solution), injections are spaced out to every 2-4 weeks. This phase usually lasts 3 to 5 years.

Oral/Herbal Use

There is no standardized FDA-approved dose for oral ingestion of the flowering top. Traditional preparations often involve 4.5 to 9 grams of the dried herb steeped in hot water. However, clinical pharmacologists caution against self-dosing due to the variability in artemisinin content.

Diagnostic Use

Artemisia Annua extracts are approved for diagnostic use in children as young as 2 years old, depending on the clinician's assessment of the child's allergic history. The procedure is identical to adult testing but may require fewer test sites to minimize distress.

Immunotherapy

Pediatric immunotherapy is generally reserved for children aged 5 and older who demonstrate significant symptoms that are not controlled by standard medications (antihistamines/nasal steroids). Dosing is weight-independent but must be titrated carefully to avoid systemic reactions.

Renal Impairment

No specific dosage adjustments are provided for the allergenic extract in renal impairment, as systemic absorption is minimal. For oral preparations, caution is advised as the kidneys are involved in the excretion of metabolites.

Hepatic Impairment

Since the liver (CYP450 system) is the primary site of metabolism for Artemisia compounds, patients with significant hepatic dysfunction should be monitored closely for signs of toxicity if using oral forms. For allergenic extracts, no adjustment is typically necessary.

Elderly Patients

Geriatric patients may have a higher prevalence of underlying cardiovascular disease. Because the extract may have adrenergic properties (alpha and beta-agonist activity), elderly patients should be screened for heart conditions before starting immunotherapy, as an accidental systemic reaction (anaphylaxis) could be more dangerous in this population.

• Immunotherapy Injections: These MUST be administered in a clinical setting equipped with emergency resuscitation equipment (epinephrine, oxygen, IV fluids).
• Observation: Patients must remain in the clinic for at least 30 minutes following an injection to monitor for anaphylaxis.
• Oral Forms: If taking as a supplement (under medical supervision), it is often recommended to take with a small amount of fat (e.g., milk or yogurt) to enhance the absorption of lipophilic sesquiterpenes, though food interactions can be complex.
• Storage: Liquid extracts should be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze.

In the context of immunotherapy, a missed dose can disrupt the desensitization process.

• If a dose is missed during the build-up phase, the next dose may need to be reduced to the previous tolerated level.
• If a dose is missed for more than 4 weeks during the maintenance phase, the physician may need to restart the build-up or significantly reduce the dose to ensure safety.

Signs of an 'overdose' in the context of an allergenic extract usually manifest as a systemic allergic reaction or anaphylaxis. Symptoms include generalized hives (urticaria), swelling of the throat (angioedema), wheezing, and a drop in blood pressure.

For oral ingestion, overdose may lead to gastrointestinal distress, dizziness, or in extreme cases, neurotoxicity (tremors, seizures). Immediate emergency medical attention is required. Treatment is supportive, often involving the administration of epinephrine for allergic reactions or activated charcoal for recent oral ingestions.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.

When used as an allergenic extract, the most frequent side effects are localized to the site of administration.

• Local Swelling: A 'wheal' or hard bump at the injection site that may be itchy or red. This typically peaks at 30 minutes and subsides within 24 hours.
• Pruritus (Itching): Intense itching at the site of the skin test or injection.
• Erythema: Redness of the skin surrounding the application area.

When taken orally as a tea or supplement:

• Abdominal Pain: Mild cramping or discomfort in the upper gastric region.
• Nausea: A feeling of sickness, often occurring shortly after ingestion.

• Large Local Reactions: Swelling that exceeds 5-10 cm in diameter at the injection site. This may require the use of ice packs or topical corticosteroids.
• Fatigue: A general sense of tiredness or 'brain fog' following an immunotherapy session.
• Headache: Mild to moderate tension-type headaches.
• Dizziness: A transient feeling of lightheadedness.

• Urticaria (Hives): Hives appearing on parts of the body distant from the injection site, indicating a systemic spread of the allergen.
• Rhinitis: Sudden onset of sneezing, runny nose, or nasal congestion shortly after administration.
• Elevated Liver Enzymes: In rare cases of high-dose oral use, transient elevations in AST/ALT have been reported.

> Warning: Stop taking Artemisia Annua Flowering Top and call your doctor immediately if you experience any of these.

• Anaphylaxis: This is the most critical risk. It involves a multi-system allergic reaction characterized by a rapid pulse, difficulty breathing, swelling of the tongue or throat, and fainting. It is a medical emergency.
• Bronchospasm: Sudden constriction of the airways causing wheezing and shortness of breath, particularly in patients with pre-existing asthma.
• Angioedema: Deep tissue swelling, most commonly around the eyes, lips, or throat, which can obstruct the airway.
• Hypotension: A dangerous drop in blood pressure that may lead to shock.
• Neurotoxicity: While rare with Artemisia annua (which has lower thujone levels than Artemisia absinthium), symptoms like seizures or severe tremors require immediate evaluation.

Long-term use of Artemisia annua flowering top as a supplement has not been extensively studied in large-scale human trials. Potential concerns include:

• Cumulative Hepatotoxicity: Prolonged exposure to certain sesquiterpene lactones may stress liver function.
• Immune Modulation: While the goal of immunotherapy is beneficial immune modulation, any long-term shift in the immune system requires professional monitoring to ensure it does not predispose the patient to other sensitivities.
• Endocrine Effects: Due to its potential Estrogen Receptor Agonist activity, long-term use could theoretically influence hormone-sensitive conditions, although clinical evidence is currently lacking.

No FDA black box warnings specifically exist for the raw "Artemisia Annua Flowering Top" herb. However, all Allergenic Extracts (the clinical drug form) carry a general warning regarding the risk of severe non-fatal and fatal systemic reactions.

Summary of Warning: Allergenic extracts should only be administered by physicians who are exceptionally familiar with the treatment of hypersensitivity and have the facilities to manage anaphylaxis. Patients with unstable asthma are at a higher risk for fatal reactions and must be evaluated carefully before each dose.

Report any unusual symptoms to your healthcare provider.

Artemisia Annua Flowering Top is a potent biological and pharmacological agent. It should never be used for self-treatment of serious infections like malaria, as the whole plant material does not provide a reliable or sufficient dose of artemisinin to ensure complete parasite clearance, which can lead to drug-resistant malaria. Furthermore, its use as an allergen must be strictly controlled to prevent life-threatening allergic reactions.

No FDA black box warnings for Artemisia Annua Flowering Top specifically as a botanical. However, as noted in the side effects section, the Allergenic Extract class (which this ingredient falls under) carries a class-wide warning regarding the risk of Anaphylaxis. This requires administration in a healthcare setting with a minimum 30-minute post-injection observation period.

• Allergic Reactions / Anaphylaxis Risk: Patients with a known severe allergy to other members of the Asteraceae family (e.g., ragweed, daisies, marigolds, chrysanthemums) are at a significantly higher risk of cross-reactivity and severe reactions to Artemisia Annua extracts.
• Asthma Stability: If you have asthma, it must be well-controlled before receiving an injection of this extract. An asthma flare-up significantly increases the risk that a systemic reaction to the extract will become fatal.
• Hepatotoxicity: There have been isolated reports of liver injury associated with concentrated Artemisia extracts. Patients with pre-existing liver disease should exercise extreme caution.
• Cardiovascular Risk: Because this substance may act as an alpha and beta-adrenergic agonist, it may increase heart rate or blood pressure. Patients with severe hypertension or unstable angina may not be candidates for this treatment.
• Estrogen Sensitivity: Patients with a history of estrogen-dependent cancers (such as certain breast or uterine cancers) should discuss the phytoestrogenic potential of this plant with their oncologist.

If you are undergoing long-term immunotherapy or taking oral Artemisia preparations, your doctor may require the following:

• Peak Flow Monitoring: For asthmatic patients to ensure lung function is stable before injections.
• Liver Function Tests (LFTs): Periodic monitoring of ALT, AST, and bilirubin if taking oral supplements.
• Skin Site Assessment: Monitoring for the size and duration of local reactions to guide dose adjustments.

Generally, Artemisia Annua does not cause sedation. However, if a patient experiences a systemic reaction or receives epinephrine to treat a reaction, they should not drive or operate machinery until they have fully recovered and been cleared by a medical professional.

Alcohol may increase the rate of absorption of certain phytochemicals and can also cause vasodilation, which might theoretically increase the risk or severity of an allergic reaction. It is advisable to avoid alcohol consumption for several hours before and after receiving an allergenic injection.

If you decide to stop allergen immunotherapy, you should consult your allergist. Stopping abruptly will result in a loss of the immunological tolerance built up during the treatment, and your allergy symptoms will likely return during the next pollen season. There is no 'withdrawal syndrome' associated with the botanical itself, but the underlying condition (allergy) will no longer be suppressed.

> Important: Discuss all your medical conditions with your healthcare provider before starting Artemisia Annua Flowering Top.

• Beta-Blockers (e.g., Propranolol, Metoprolol): Patients taking beta-blockers should generally not receive allergenic extracts. If a systemic reaction occurs, beta-blockers can make the reaction more severe and render the standard treatment (epinephrine) ineffective.
• MAO Inhibitors (e.g., Phenelzine, Selegiline): Due to the potential alpha-Adrenergic Agonist properties of Artemisia Annua, use with MAOIs could lead to a hypertensive crisis (dangerously high blood pressure).

• ACE Inhibitors: May increase the risk of systemic reactions or more severe angioedema during immunotherapy.
• Antidiabetic Medications: Some studies suggest Artemisia annua may lower blood glucose levels. When combined with insulin or oral hypoglycemics (like Metformin), there is an increased risk of hypoglycemia (low blood sugar).
• Tricyclic Antidepressants (TCAs): May potentiate the adrenergic effects of the extract, leading to increased cardiovascular strain.

• CYP3A4 and CYP2C19 Inducers/Inhibitors: Since artemisinin is metabolized by these enzymes, drugs like Rifampin (inducer) or Ketoconazole (inhibitor) can significantly alter the levels of active compounds in the body.
• Warfarin: Artemisia may have mild antiplatelet effects or interfere with metabolism, potentially altering the International Normalized Ratio (INR) and increasing bleeding risk.

• Grapefruit Juice: Known to inhibit CYP3A4, grapefruit juice may increase the systemic concentration of the plant's sesquiterpene lactones, potentially increasing the risk of side effects.
• High-Fat Meals: May significantly increase the absorption of artemisinin and other lipophilic constituents, leading to unpredictable blood levels.

• St. John's Wort: A potent inducer of CYP3A4, which may reduce the efficacy of the active compounds in Artemisia.
• Other Asteraceae Herbs: Taking supplements like Echinacea or Chamomile may increase the total 'allergic load' and increase the risk of a hypersensitivity reaction in sensitive individuals.
• Phytoestrogens (e.g., Soy, Red Clover): May have additive effects with the Estrogen Receptor Agonist properties of Artemisia.

• Skin Testing: If you are taking antihistamines (like Loratadine or Cetirizine), you must stop them 3-7 days before a skin test with Artemisia extract, as they will suppress the wheal and flare response, leading to a false-negative result.
• Liver Function Tests: May show transient elevations that could be misinterpreted as other forms of hepatitis.

For each major interaction, the mechanism often involves competitive inhibition of CYP enzymes or pharmacodynamic synergism (where two drugs have similar effects on the body). The clinical consequence is usually an increased risk of toxicity or a decrease in the effectiveness of the medication. Management strategies involve dose timing adjustments, increased monitoring, or choosing alternative therapies.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

• Severe, Uncontrolled Asthma: Patients whose asthma is not stable are at the highest risk for fatal anaphylaxis during allergen immunotherapy. The risk of bronchospasm outweighs any potential benefit of the extract.
• Known Hypersensitivity to Artemisia: If a patient has previously experienced a life-threatening reaction to Artemisia annua or its components, further use is strictly prohibited.
• Recent Myocardial Infarction (Heart Attack): Due to the adrenergic (alpha and beta-agonist) potential, the cardiac strain of a potential systemic reaction is an absolute contraindication in the acute recovery phase of a heart attack.

• Beta-Blocker Therapy: As mentioned, this makes treating a systemic reaction difficult. A risk-benefit analysis must be performed by the physician.
• Autoimmune Diseases: There is a theoretical risk that stimulating the immune system via immunotherapy could exacerbate certain autoimmune conditions like Lupus or Rheumatoid Arthritis.
• Pregnancy (Initiation): While maintenance immunotherapy can often be continued during pregnancy, starting a new course of Artemisia extract is generally avoided due to the risk of anaphylaxis-induced fetal hypoxia.
• Malignancy: Patients with active cancer may have altered immune responses, making the results of immunotherapy unpredictable.

Patients should be aware of cross-sensitivity within the Asteraceae (Compositae) family. If you are allergic to the following, you may also react to Artemisia Annua Flowering Top:

• Ragweed (Ambrosia)
• Chrysanthemums
• Marigolds
• Daisies
• Sunflowers
• Dandelions

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Artemisia Annua Flowering Top.

FDA Pregnancy Category: Not formally assigned, but generally considered Category C.

• Risks: There is limited data on the teratogenic effects of Artemisia annua flowering top in humans. However, animal studies on artemisinin derivatives have shown evidence of embryo-fetal toxicity (embryolethality) in early pregnancy.
• Immunotherapy: The primary risk during pregnancy is maternal anaphylaxis, which can lead to a sudden drop in blood pressure and oxygen delivery to the fetus, potentially causing miscarriage or neurological damage.
• Recommendation: Initiation of Artemisia immunotherapy during pregnancy is not recommended. Maintenance therapy may continue if the benefit to the mother's respiratory health is significant.

It is unknown if the specific proteins or phytochemicals from Artemisia Annua Flowering Top pass into human breast milk. Many small molecules (like artemisinin) are likely to be excreted in small amounts. Because the safety for nursing infants has not been established, caution should be exercised. The risk of the infant developing a sensitization to the herb through breast milk is a theoretical concern.

• Approved Age: Diagnostic testing is common in children over age 2. Immunotherapy is typically reserved for children 5 years and older.
• Considerations: Children may be more prone to 'late-phase' local reactions. Growth effects have not been observed with allergenic extracts, unlike long-term systemic corticosteroid use.
• Contraindications: Children with severe eczema or unstable asthma should be treated with extreme caution.

• Cardiovascular Health: Elderly patients must be screened for arrhythmias and coronary artery disease, as these conditions increase the risk of complications from a systemic reaction.
• Polypharmacy: Older adults are more likely to be on medications like beta-blockers or ACE inhibitors, which interact with the extract.
• Renal Function: Age-related decline in GFR may slow the clearance of any systemically absorbed phytochemicals.

While the allergenic extract is not known to be nephrotoxic, the kidneys are responsible for clearing the metabolites of the plant's various sesquiterpenes. Patients with a GFR < 30 mL/min should avoid high-dose oral supplements of Artemisia.

In patients with Child-Pugh Class B or C hepatic impairment, the metabolism of the plant's active constituents (via CYP450) will be significantly delayed. This increases the risk of systemic toxicity if the flowering top is ingested. For allergenic injections, the risk is lower but still warrants careful monitoring for systemic symptoms.

> Important: Special populations require individualized medical assessment.

Artemisia Annua Flowering Top acts through several distinct pathways:

1. 1Immunological Desensitization: As an allergenic extract, it interacts with B-cells and T-cells to modulate the production of cytokines. It promotes the shift from IL-4/IL-5 (pro-allergic) to IFN-gamma and IL-10 (anti-inflammatory/regulatory) production.
2. 2Endoperoxide Activity: The artemisinin within the flowering top contains an endoperoxide bridge. In the presence of free iron (abundant in malaria parasites), this bridge breaks, creating free radicals that damage biological membranes and proteins.
3. 3Adrenergic Interaction: Certain volatile oils in the flowering top act as Adrenergic alpha and beta agonists, which can induce mild vasoconstriction or bronchodilation depending on the specific receptor affinity.
4. 4Estrogenic Activity: Flavonoids like casticin act as selective estrogen receptor modulators (SERMs), binding to ER receptors and exerting weak estrogenic or anti-estrogenic effects.

• Onset of Action: For skin testing, 15-30 minutes. For immunotherapy, clinical improvement in allergy symptoms usually takes 6-12 months of consistent treatment.
• Duration of Effect: A single skin test reaction lasts 24 hours. The immunological 'memory' created by a full course of immunotherapy can last for years or even decades.

| Parameter | Value |

|---|---|

| Bioavailability | < 30% (Oral, highly variable) |

| Protein Binding | 40% - 80% (Artemisinin components) |

| Half-life | 2 - 5 hours (Active metabolites) |

| Tmax | 1 - 2 hours (Oral ingestion) |

| Metabolism | Hepatic (CYP3A4, CYP2B6, CYP2C19) |

| Excretion | Renal (< 10% unchanged), Fecal (Primary) |

• Molecular Components: Contains artemisinin (C15H22O5), artemisinic acid, and various essential oils.
• Solubility: Active sesquiterpenes are poorly soluble in water but highly soluble in lipids and organic solvents.
• Structure: The hallmark is the cadinane-type sesquiterpene lactone with a unique peroxide group.

Artemisia Annua Flowering Top is classified as a Non-Standardized Plant Allergenic Extract. It shares this class with other ragweed and sagebrush extracts. It is also functionally grouped with Adrenergic Agonists and Estrogen Receptor Agonists in specialized pharmacological databases due to its secondary metabolites.